Verona Pharma Inc

Quick facts

Phase 2 pipeline

• Ensifentrine Dose 1 · Respiratory
  Ensifentrine is a dual inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC).

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Verona Pharma Inc portfolio CI brief
• Verona Pharma Inc pipeline updates RSS